New targeted drug may improve lymphoma treatment

NCT ID NCT07372365

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with untreated marginal zone lymphoma, a slow-growing blood cancer. Participants first get a short course of standard chemotherapy, then a targeted drug called orelabrutinib to keep the cancer under control. The goal is to see if this combination improves response rates and delays the cancer's return. About 23 people will take part, and they will be closely monitored for side effects and treatment success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib (a targeted drug) combined with R-CHOP chemotherapy and rituximab
What this could lead to: If successful, this could offer a more effective and less toxic treatment plan for people with newly diagnosed marginal zone lymphoma, potentially improving long-term disease control.
What could go wrong: This is a small, early-phase study with only 23 participants, so results may not apply to everyone. The drug may cause side effects, and the treatment may not work better than current options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA (MZL)

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.